Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CollaGenex seeks UK approval for Oracea
The marketing authorization application (MAA) was based primarily upon safety and efficacy results from two phase III clinical trials for Oracea. In the two studies, patients receiving Oracea
The marketing authorization application (MAA) was based primarily upon safety and efficacy results from two phase III clinical trials for Oracea. In the two studies, patients receiving Oracea
Cardiosphere, a myocardial perfusion agent, is used with ultrasound imaging for the detection and localization of obstructive coronary artery disease. If approved for marketing, the company says that
The study will enroll approximately 64 healthy men and women between the ages of 65 and 80, reflecting the age of the primary Alzheimer’s disease population. Investigators will
ViroPharma plans to initially focus its efforts on the opportunity to prevent recurrence of clostridium difficile-associated disease (CDAD) following treatment with Vancocin. The company is currently conducting feasibility
The cell line could be used to manufacture HuMax-TAC for clinical trials. HuMax-TAC is a fully human monoclonal antibody that may have therapeutic potential in the treatment of
In studies conducted at Brigham and Women’s Hospital of the Harvard University School of Medicine, AZD-103 was shown to be highly effective at neutralizing the short term effects
MyVax personalized immunotherapy is based on the unique genetic makeup of a patient’s own tumor, and is designed to activate the patient’s immune system to fight cancer. Nine
Tarvacin Anti-Viral is the first in a new class of anti-phosphotidylserine (PS) immunotherapeutics that targets and binds to cellular components that are normally not present on the outside
Additional follow-up of the hormone-refractory prostate cancer (HRPC) patients who received a dose comparable to that used in the company’s ongoing phase III program indicates that the median
To give the good news first, Avant revealed that it will get a $40 million royalty payment from GlaxoSmithKline now the company’s co-developed vaccine Rotarix has gained approval